Background: Despite increasingly re fi ned tools for identi-fying individuals at clinical high-risk for psychosis (CHR-P), less is known about the effectiveness of interventions for CHR-P. The signi fi cant clinical heterogeneity among CHR-P individuals is a notable barrier, suggesting that interventions may need to be personalized during this emerging phase of illness. To address these gaps, the...
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...